Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating...

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Gastroenterology

Background:

• KPV (Lys-Pro-Val) exhibits anti-inflammatory effects for colitis treatment.
• Rectal administration of KPV solutions is limited by instability, reducing therapeutic efficacy.

Purpose of the Study:

• To develop a stable KPV-loaded hydrogel for improved ulcerative colitis therapy.
• To evaluate the therapeutic potential of cysteamine-grafted γ-polyglutamic acid (SH-PGA) hydrogel loaded with KPV.

Main Methods:

• Synthesized cysteamine-grafted γ-polyglutamic acid (SH-PGA) via self-cross-linking.
• Formulated KPV/SH-PGA hydrogel with enhanced mechanical stability and shear-thinning properties.
• Assessed KPV stability, release kinetics, and anti-inflammatory activity in vitro.
• Evaluated the therapeutic efficacy in a TNBS-induced ulcerative colitis rat model.

Main Results:

• SH-PGA hydrogel formed stable KPV encapsulation with sustained release.
• KPV stability and therapeutic potential were significantly enhanced in the hydrogel.
• KPV/SH-PGA hydrogel treatment attenuated colitis symptoms and restored colon morphology in rats.
• Reduced levels of pro-inflammatory cytokines (TNF-α, IL-6) and myeloperoxidase were observed.

Conclusions:

• KPV/SH-PGA hydrogel offers a promising, stable drug delivery system for ulcerative colitis.
• The developed hydrogel enhances KPV stability and therapeutic outcomes.
• This strategy holds potential for effective ulcerative colitis management.